Introduction:
Nowadays, anti-vascular endothelial growth factor (VEGF) therapy is widely used as first-line therapy for retinopathy of prematurity (ROP) with very good therapeutic and visual results.
Aim:
The aim of the present study is to compare the efficacy and safety outcomes between different anti-VEGF drugs.
Materials and Methods:
For the period January 2005–April 2023, in the available database (PubMed, Web of Science, Scopus), a systematic analysis of scientific publications examining the impact of anti-VEGF drugs on ROP was conducted.
Results:
Anti-VEGF drugs inhibit the second phase of pathogenesis of ROP, which is characterised by excessive production of VEGFs. In the last 15 years, many clinical trials comparing the efficacy of different concentraionts of the drugs, safety, ocular and systemic outcomes have been conducted.
Conclusion:
There are several advantages of anti-VEGF therapy, such as easier application, earlier regression of ROP, peripheral vascularisation of the retina, and lower risk of myopia.
Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(S1):35-49. doi:10.1038/pr.2013.205.
Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J Am Assoc Pediatr Ophthalmol Strabismus. 2010;14(1):2-3. doi:10.1016/j.jaapos.2009.12.002.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-15. doi:10.1056/NEJMoa1007374.
Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: A randomized clinical trial. JAMA Pediatr. 2018;172(3):278. doi:10.1001/jamapediatrics.2017.4838.
Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5(10):698-707. doi:10.1016/S2352-4642(21)00195-4.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85. doi:10.1007/s10456-011-9249-6.
Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667-8. doi:10.1136/bjo.2007.134874.
Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256(3):479-87. doi:10.1007/s00417-017-3878-4.
Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: The FIREFLEYE randomized clinical trial. JAMA. 2022;328(4):348. doi:10.1001/jama.2022.10564.
Autrata R, Krejčířová I, Šenková K, Holoušová M, Doležel Z, Borek I. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012;22(5):687-94. doi:10.5301/ejo.5000166.
Wu Z, Zhao J, Lam W, Yang M, Chen L, Huang X, et al. Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial. Br J Ophthalmol. 2022;106(7):975-9. doi:10.1136/bjophthalmol-2020-318026.
Beck KD, Rahman EZ, Ells A, Mireskandari K, Berrocal AM, Harper CA. SAFER-ROP: updated protocol for anti-VEGF Injections for retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020;51(7):402-6. doi:10.3928/23258160-20200702-05.
Tran KD, Cernichiaro-Espinosa LA, Berrocal AM. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy. Asia Pac J Ophthalmol (Phila). 2018;7(1):56-62. doi: 10.22608/APO.2017436.